caa a22 4500 477056849 CHVBK 20180405111348.0 cr unu---uuuuu 170330e19961001xx s 000 0 eng 10.1007/s002280050169 doi (NATIONALLICENCE)springer-10.1007/s002280050169 Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancer [Elektronische Daten] [A. Messori, P. Becagli, S. Trippoli, E. Tendi] Background: The analysis of published survival curves can be used as the basis for incremental cost-effectiveness analyses in which two treatments are compared with each other in terms of cost per life year saved. In patients with node-positive breast cancer adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil has been reported to improve survival in comparison with patients who are not given this treatment. Methods: To assess the pharmacoeconomic profile of this adjuvant chemotherapeutic regimen in terms of cost per life-year gained, we conducted an incremental cost-effectiveness analysis in which the Gompertz model was used to calculate the lifetime estimate of the patient-years gained by treated subjects compared to controls. Results: Using data from a published, controlled long-term trial involving 207 patients treated with cyclophosphamide + methotrexate + fluorouracil and 179 controls, we estimated that this adjuvant chemotherapy improved life expectancy by 357 patient-years per 100 subjects. Direct costs, which were almost exclusively related to the administration of chemotherapy, were estimated to be US $159,516 per 100 patients. On the basis of these data, adjuvant chemotherapy was found to imply an incremental cost of US $447 per life-year saved. Conclusions: The cost-effectiveness ratio of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancer seems to be particularly favourable in comparison with estimates of cost per life-year saved previously calculated for other types of pharmacological intervention. Springer-Verlag Berlin Heidelberg, 1996 Key words Adjuvant chemotherapy nationallicence Breast cancer nationallicence pharmacoeconomics nationallicence cost-effectiveness analysis nationallicence Messori A. Meta-analysis Study Group of SIFO (Italian Society of Hospital Pharmacists), c/o Drug Information Centre, Pharmaceutical Service, Azienda Ospedaliera Careggi, viale Morgagni 85, I-50136 Florence, Italy, IT aut Becagli P. Meta-analysis Study Group of SIFO (Italian Society of Hospital Pharmacists), c/o Drug Information Centre, Pharmaceutical Service, Azienda Ospedaliera Careggi, viale Morgagni 85, I-50136 Florence, Italy, IT aut Trippoli S. Meta-analysis Study Group of SIFO (Italian Society of Hospital Pharmacists), c/o Drug Information Centre, Pharmaceutical Service, Azienda Ospedaliera Careggi, viale Morgagni 85, I-50136 Florence, Italy, IT aut Tendi E. Meta-analysis Study Group of SIFO (Italian Society of Hospital Pharmacists), c/o Drug Information Centre, Pharmaceutical Service, Azienda Ospedaliera Careggi, viale Morgagni 85, I-50136 Florence, Italy, IT aut https://doi.org/10.1007/s002280050169 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280050169 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Messori A. Meta-analysis Study Group of SIFO (Italian Society of Hospital Pharmacists), c/o Drug Information Centre, Pharmaceutical Service, Azienda Ospedaliera Careggi, viale Morgagni 85, I-50136 Florence, Italy, IT aut NATIONALLICENCE 700 1- Becagli P. Meta-analysis Study Group of SIFO (Italian Society of Hospital Pharmacists), c/o Drug Information Centre, Pharmaceutical Service, Azienda Ospedaliera Careggi, viale Morgagni 85, I-50136 Florence, Italy, IT aut NATIONALLICENCE 700 1- Trippoli S. Meta-analysis Study Group of SIFO (Italian Society of Hospital Pharmacists), c/o Drug Information Centre, Pharmaceutical Service, Azienda Ospedaliera Careggi, viale Morgagni 85, I-50136 Florence, Italy, IT aut NATIONALLICENCE 700 1- Tendi E. Meta-analysis Study Group of SIFO (Italian Society of Hospital Pharmacists), c/o Drug Information Centre, Pharmaceutical Service, Azienda Ospedaliera Careggi, viale Morgagni 85, I-50136 Florence, Italy, IT aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer